OncoCyte Corporation (OCX)

2.4800 +0.0400 (+1.64%) At close: 04:00PM EDT

OncoCyte Corporation

15 Cushing
Irvine, CA 92618
United States
949 409 7600
https://www.oncocyte.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full Time Employees: 43

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Joshua Riggs	President, CEO & Director	373.2k	N/A	1983
Mr. James Liu	Senior Director, Controller, Principal Accounting Officer & Interim Principal Financial Officer	192.48k	N/A	1996
Dr. Ekkehard Schutz M.D., Ph.D.	Chief Science Officer	N/A	N/A	N/A
Mr. Peter Hong	VP, General Counsel & Secretary	N/A	N/A	N/A
Mr. Yuh-Min Chiang Ph.D.	Senior Vice President of R&D and Product Development	N/A	N/A	N/A
Ms. Sandra O'Donald	Senior Vice President of Business Operations	N/A	N/A	N/A
Dr. Michael D. West Ph.D.	Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc.	N/A	N/A	1953
Ms. Sara Riordan	Director of Medical Education	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Corporate Governance

OncoCyte Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.